Lexaria Bioscience Corp. announced on February 11, 2025, that it has been granted two new patents from the United States Patent and Trademark Office. These patents are for the use of DehydraTECH enhanced processing technology related to the treatment of epilepsy.
These additions represent the 5th and 6th US patents granted in Lexaria's patent family #24, 'Compositions and Methods for Treating Epilepsy'. The new patents are set to expire in 2043, if not extended, and increase Lexaria's total granted patent count to 48.
The expansion of intellectual property in the epilepsy market, which was valued at US$9.5 billion in 2023 and is projected to exceed $15 billion by 2032, enhances Lexaria's commercial criticality and value for potential pharmaceutical partners.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.